Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
Dow
Boehringer Ingelheim
McKesson

Last Updated: February 7, 2023

Voxelotor - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic drug sources for voxelotor and what is the scope of freedom to operate?

Voxelotor is the generic ingredient in one branded drug marketed by Global Blood Theraps and is included in two NDAs. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Voxelotor has two hundred and forty-seven patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for voxelotor
International Patents:247
US Patents:10
Tradenames:1
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 45
Clinical Trials: 16
Patent Applications: 153
What excipients (inactive ingredients) are in voxelotor?voxelotor excipients list
DailyMed Link:voxelotor at DailyMed
Recent Clinical Trials for voxelotor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duke UniversityPhase 2
Assistance Publique - Hôpitaux de ParisPhase 2
Global Blood Therapeutics (GBT)Phase 2

See all voxelotor clinical trials

US Patents and Regulatory Information for voxelotor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Global Blood Theraps OXBRYTA voxelotor TABLET;ORAL 213137-001 Nov 25, 2019 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for voxelotor

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Global Blood Therapeutics Netherlands B. V. Oxbryta Voxelotor EMEA/H/C/004869
Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.
Authorised no no yes 2022-02-14
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for voxelotor

Country Patent Number Title Estimated Expiration
Chile 2015002567 Compuestos y sus usos para modular la hemoglobina See Plans and Pricing
Australia 2015214182 Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde See Plans and Pricing
Chile 2015002501 Compuestos y usos de estos para la modulación de la hemoglobina See Plans and Pricing
European Patent Office 3919056 COMPOSÉS ET LEURS UTILISATIONS POUR LA MODULATION DE L'HÉMOGLOBINE (COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for voxelotor

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2797416 LUC00276 Luxembourg See Plans and Pricing PRODUCT NAME: VOXELOTOR OR A TAUTOMER OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/21/1622 20220215
2797416 PA2022517 Lithuania See Plans and Pricing PRODUCT NAME: VOKSELOTORAS ARBA TAUTOMERAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1622 20220214
2797416 301191 Netherlands See Plans and Pricing PRODUCT NAME: VOXELOTOR OF EEN TAUTOMEER OF FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/21/1622 20220215
2797416 122022000052 Germany See Plans and Pricing PRODUCT NAME: VOXELOTOR ODER EIN TAUTOMER ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1622 20220214
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Colorcon
Mallinckrodt
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.